Contrasting Inhibrx (NASDAQ:INBX) and Taysha Gene Therapies (NASDAQ:TSHA)

Inhibrx (NASDAQ:INBX) and Taysha Gene Therapies (NASDAQ:TSHA) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their risk, valuation, analyst recommendations, profitability, earnings, dividends and institutional ownership.

Profitability

This table compares Inhibrx and Taysha Gene Therapies’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Inhibrx	N/A	N/A	N/A
Taysha Gene Therapies	-888.18%	-168.91%	-44.12%

Valuation & Earnings

This table compares Inhibrx and Taysha Gene Therapies”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Inhibrx	$1.69 million	135.06	-$154.96 million	N/A	N/A
Taysha Gene Therapies	$12.87 million	28.33	-$111.57 million	($0.49)	-3.98

Taysha Gene Therapies has higher revenue and earnings than Inhibrx.

Institutional and Insider Ownership

82.5% of Inhibrx shares are held by institutional investors. Comparatively, 77.7% of Taysha Gene Therapies shares are held by institutional investors. 22.2% of Inhibrx shares are held by company insiders. Comparatively, 2.7% of Taysha Gene Therapies shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Analyst Recommendations

This is a summary of current ratings for Inhibrx and Taysha Gene Therapies, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Inhibrx	0	2	0	0	2.00
Taysha Gene Therapies	0	0	8	0	3.00

Inhibrx currently has a consensus target price of $27.00, suggesting a potential upside of 71.54%. Taysha Gene Therapies has a consensus target price of $6.38, suggesting a potential upside of 226.92%. Given Taysha Gene Therapies’ stronger consensus rating and higher possible upside, analysts clearly believe Taysha Gene Therapies is more favorable than Inhibrx.

Summary

Inhibrx beats Taysha Gene Therapies on 6 of the 11 factors compared between the two stocks.

About Inhibrx

Inhibrx, Inc., a clinical-stage biopharmaceutical company, develops a pipeline of novel biologic therapeutic candidates. The company's therapeutic candidate includes INBRX-101, an alpha-1 antitrypsin (AAT)-Fc fusion protein therapeutic candidate, which is in Phase 1 clinical trials for use in the treatment of patients with AAT deficiency. It also develops INBRX-109, a tetravalent therapeutic candidate targeting death receptor 5, which is in Phase 2 clinical trials to treat cancers, such as chondrosarcoma, mesothelioma, colorectal cancer, ewing sarcoma, and pancreatic adenocarcinoma; and INBRX-106, a hexavalent agonist of OX40 for a range of oncology indications. The company has license and collaboration agreements with 2seventy bio, Inc. and Bristol-Myers Squibb Company. Inhibrx, Inc. was incorporated in 2009 and is headquartered in La Jolla, California.

About Taysha Gene Therapies

Taysha Gene Therapies, Inc., a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of for SLC13A5 deficiency; TSHA-113 for the treatment of tauopathies; TSHA-106 for the treatment of angelman syndrome; TSHA-114 for the treatment of fragile X syndrome; and TSHA-101 for the treatment of GM2 gangliosidosis. Taysha Gene Therapies, Inc. has a strategic partnership with The University of Texas Southwestern Medical Center. Taysha Gene Therapies, Inc. was incorporated in 2019 and is headquartered in Dallas, Texas.